MindWalk Holdings Corp. (NASDAQ:HYFT) Receives $5.00 Consensus Target Price from Brokerages

MindWalk Holdings Corp. (NASDAQ:HYFT) has been assigned an average rating of “Hold” from the five ratings firms that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $5.00.

HYFT has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a research report on Wednesday, July 15th. Zacks Research downgraded MindWalk from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen raised MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

Institutional Trading of MindWalk

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in MindWalk during the fourth quarter worth $51,000. GSA Capital Partners LLP bought a new position in MindWalk during the second quarter valued at $55,000. Bridgeway Capital Management LLC purchased a new stake in shares of MindWalk in the fourth quarter valued at $91,000. Bank of Montreal Can raised its stake in shares of MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after acquiring an additional 24,500 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of MindWalk by 118.6% in the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after acquiring an additional 44,331 shares during the last quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

MindWalk Stock Performance

Shares of NASDAQ:HYFT opened at $1.41 on Wednesday. MindWalk has a 52 week low of $0.99 and a 52 week high of $3.25. The stock has a market capitalization of $65.86 million, a P/E ratio of -6.41 and a beta of 0.84. The firm has a fifty day simple moving average of $1.44 and a two-hundred day simple moving average of $1.37. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.26.

MindWalk (NASDAQ:HYFT) last posted its earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The business had revenue of $3.03 million during the quarter. MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%. On average, analysts expect that MindWalk will post -0.21 earnings per share for the current fiscal year.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.